J2351Drugs Administered Other than Oral Method

Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq

Short description: Inj ocrelizumab 1mg hya-ocsq

Effective date: April 1, 2025
Termination date: —

Related codes (J-series)

J0013Esketamine, nasal spray J0014Cocaine hcl nasal (goprelto)J0120Tetracyclin injection J0121Inj., omadacycline, 1 mg J0122Inj., eravacycline, 1 mg J0129Abatacept injection J0130Abciximab injection J0131Inj, acetaminophen (nos)J0132Acetylcysteine injection J0133Acyclovir injection J0134Inj acetaminophen -fresenius J0135Adalimumab injection

Frequently asked questions

What is HCPCS code J2351?

J2351 is a HCPCS Level II code for Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq.

What category is HCPCS code J2351 in?

J2351 falls under the Drugs Administered Other than Oral Method category of HCPCS Level II.

When did HCPCS code J2351 become effective?

J2351 has been effective since April 1, 2025, per CMS's quarterly HCPCS update.

HCPCS Level II data from CMS (public domain). HCPCS Level I (CPT) codes are not included — CPT is copyrighted by the American Medical Association. Always verify codes with authoritative sources before making coding or billing decisions.